GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (NAS:CLNN) » Definitions » Pretax Margin %

Clene (CLNN) Pretax Margin % : -15,178.08% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Clene Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Clene's Pre-Tax Income for the three months ended in Mar. 2024 was $-11.08 Mil. Clene's Revenue for the three months ended in Mar. 2024 was $0.07 Mil. Therefore, Clene's pretax margin for the quarter that ended in Mar. 2024 was -15,178.08%.

The historical rank and industry rank for Clene's Pretax Margin % or its related term are showing as below:

CLNN' s Pretax Margin % Range Over the Past 10 Years
Min: -9160.68   Med: -6947.29   Max: -1406.36
Current: -7873.23


CLNN's Pretax Margin % is ranked worse than
89.08% of 1026 companies
in the Biotechnology industry
Industry Median: -154.275 vs CLNN: -7873.23

Clene Pretax Margin % Historical Data

The historical data trend for Clene's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clene Pretax Margin % Chart

Clene Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
- -9,160.68 -1,406.36 -6,325.16 -7,569.42

Clene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11,000.00 -9,346.84 -2,238.89 -5,984.12 -15,178.08

Competitive Comparison of Clene's Pretax Margin %

For the Biotechnology subindustry, Clene's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clene's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clene's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Clene's Pretax Margin % falls into.



Clene Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Clene's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-49.504/0.654
=-7,569.42 %

Clene's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-11.08/0.073
=-15,178.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clene  (NAS:CLNN) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Clene Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Clene's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clene (CLNN) Business Description

Traded in Other Exchanges
Address
6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).
Executives
David J Matlin director
Matthew Kiernan director 500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Arjun Jj Desai director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Robert Dee Etherington director, officer: Chief Executive Officer 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
John Henry Stevens director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Chidozie Ugwumba director 158 FILMORE STREET, DENVER CO 80206
Alison Mosca director 26 PATRIOT PLACE, SUITE 301, FOXBORO MA 02035
Jonathon Gay director 177 HUNTINGTON AVENUE, 21ST FLOOR, BOSTON MA 02115
General Resonance Llc 10 percent owner 6510 SOUTH MILLROCK DRIVE, SUITE 250, HOLLADAY UT 84121
Robert Glanzman officer: Chief Medical Officer 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Morgan R Brown officer: Chief Financial Officer 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Vallerie Mclaughlin director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Mark Mortenson officer: Chief Science Officer 500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Fiona Costello director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Shalom Jacobovitz director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121